GSA Capital Partners’s Ginkgo Bioworks DNA Stock Holding History

GSA Capital Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-55,059	Closed	-$619K	–	1747
2025 Q2	$619K	Sell	55,059 -73,514	-57%	-$570K	0.04%	767
2025 Q1	$733K	Buy	+128,573	New	+$1.31M	0.07%	535
2024 Q4	–	Sell	-120,169	Closed	-$979K	–	1694
2024 Q3	$979K	Buy	120,169 +50,282	+72%	+$504K	0.07%	480
2024 Q2	$935K	Buy	+69,887	New	+$2.09M	0.07%	549
2023 Q4	–	Sell	-1,899	Closed	-$138K	–	1582
2023 Q3	$138K	Buy	+1,899	New	+$152K	0.01%	1355
2023 Q2	–	Sell	-1,815	Closed	-$97K	–	1600
2023 Q1	$97K	Sell	1,815 -1,136	-38%	-$72K	0.01%	1364
2022 Q4	$199K	Buy	2,951 +302	+11%	+$27.8K	0.02%	1190
2022 Q3	$331K	Sell	2,649 -3,447	-57%	-$411K	0.04%	860
2022 Q2	$580K	Buy	+6,096	New	+$744K	0.09%	408
2022 Q1	–	Sell	-661	Closed	-$220K	–	1500
2021 Q4	$220K	Buy	+661	New	+$314K	0.03%	1150

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSA Capital Partners's DNA Position: Q3 2025 in Review

GSA Capital Partners sold out of Ginkgo Bioworks (DNA) in Q3 2025, closing a stake of 55,059 shares — an estimated $619K sold.

GSA Capital Partners first reported a position in DNA in Q4 2021 and held it in 10 quarters. The position peaked at $979K in Q3 2024. 174 funds tracked by Wall St. Rank hold DNA as of Q3 2025.

GSA Capital Partners reported no remaining Ginkgo Bioworks position as of Q3 2025 after selling out during the quarter.
GSA Capital Partners sold 55,059 Ginkgo Bioworks shares in Q3 2025, an estimated $619K.
GSA Capital Partners first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 10 quarters.
GSA Capital Partners's Ginkgo Bioworks position peaked at $979K in Q3 2024.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.